Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.
|Articles|August 24, 2020
Microbial Factors at Work in the Wound Healing Process
Advertisement
You'll learn:
- How the gut microbiome has informed understanding of the skin microbiome
- The role of dysbiosis in chronic wounds
- Prebiotics, probiotics, postbiotics -what are these and how do they each contribute to skin
Advertisement
Related to this article
Christophe Piketty, MD, PhD, discussed 3-year findings from the ARCADIA long-term extension study and the implications of targeting IL-31 in atopic dermatitis.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
3
Litifilimab Demonstrates Durable Skin Clearance Through 52 Weeks in Cutaneous Lupus
4
Icotrokinra Sustains Skin Clearance at High-Impact Psoriasis Sites Through 2 Years
5